Objective-To assess the eYcacy and safety of intravenous dofetilide in preventing induction of atrioventricular re-entrant tachycardia. Design-A multicentre, open, dose ranging trial. Fifty one patients with electrically inducible atrioventricular re-entrant tachycardia were allocated to one of five doses of dofetilide (1.5, 3, 6, 9, and 15 µg/kg), two thirds of the dofetilide dose being given over a 15 minute loading period and the remainder over a 45 minute maintenance period. Main outcome measure-Responders were defined as patients in whom dofetilide prevented reinduction of atrioventricular re-entrant tachycardia at the end of the infusion. Results-Intravenous dofetilide had no eVect on tachycardia inducibility at the two lower doses (1.5 and 3 µg/kg) but prevented the reinduction of tachycardia at the three higher doses (6, 9, and 15 µg/kg) at a rate of 36% (11/31). There was a clear relation between plasma dofetilide concentrations and eYcacy (p = 0.009). In non-responders, dofetilide increased the cycle length of induced atrioventricular re-entrant tachycardia. Dofetilide increased the atrial and ventricular eVective refractory periods, as well as the antegrade and retrograde eVective refractory period of the accessory pathway. Treatment related side eVects were reported in four patients, one with a new sustained incessant supraventricular tachycardia. Conclusions-Dofetilide shows promise as an agent for the prevention of atrioventricular re-entrant tachycardia in patients without structural heart disease. (Heart 2001;86:522-526) 
Pharmacological treatment of supraventricular tachycardia remains a common approach despite the increased use of radiofrequency ablation. Atrioventricular re-entrant tachycardia is currently treated with various pharmacological agents. While class I antiarrhythmic drugs are eVective in treating this form of tachycardia, there is a reluctance to use these agents, especially in patients with structural heart disease, because of potential proarrhythmia or undesirable side eVects-as seen in the cardiac arrhythmia suppression trial (CAST). 1 2 The most common class III antiarrhythmic agents (amiodarone and sotalol) are eVective but also cause undesirable side eVects. [3] [4] [5] [6] [7] Calcium channel blockers have negative inotropic and chronotropic eVects and are used less often. 8 Dofetilide is a novel class III antiarrhythmic agent that produces potent and selective blockade of the rapidly activating component of the delayed rectifier current, I kr . 9 10 Studies have shown that dofetilide prolongs both atrial and ventricular monophasic action potential durations and increases atrial and ventricular eVective and functional refractory periods. Because of its selective class III antiarrhythmic eVect, dofetilide has no eVect on atrioventricular conduction or sinus node function. [11] [12] [13] Clinical reports have shown that dofetilide is eVective in the treatment of supraventricular tachyarrhythmias, such as atrial fibrillation and atrial flutter. [14] [15] [16] However, to date there have been no studies on the dose dependent eVects of dofetilide on atrioventricular re-entrant tachycardia. Our goal in this study was to assess the eYcacy of intravenous dofetilide, in five diVerent dosing regimens, for treating patients with inducible atrioventricular re-entrant tachycardia, by determining its ability to prevent reinduction of the tachycardia.
Methods

STUDY DESIGN
An open, dose ranging study was designed to evaluate the eYcacy and safety of dofetilide. Patients were recruited from eight centres. Patients with suspected supraventricular or ventricular tachyarrhythmias, or both, were referred for a routine electrophysiological evaluation. The patient was included in the study only if the results of the electrophysiological test were compatible with inducible atrioventricular re-entrant tachycardia.
Patients were assigned to one of five doses of dofetilide (1.5, 3, 6, 9, and 15 µg/kg). The total dofetilide dose was given over a one hour period, two thirds of the dose being given in an initial 15 minute loading period and the remainder over a final 45 minute maintenance period.
PATIENTS
At baseline, all patients underwent standard electrophysiological evaluation and programmed electrical stimulation to evaluate atrioventricular re-entrant tachycardia. Only patients aged 18-75 years with inducible atrioventricular re-entrant tachycardia at baseline were included in the study. Female subjects had to be of non-childbearing potential or using appropriate contraception. Before inclusion, each patient had a full clinical examination, a 12 lead ECG, and 24 hour Holter monitoring. Exclusion criteria are listed in table 1.
The protocol was approved by the local ethics committees and the study was monitored in accordance with standard operating procedures and good clinical practice. All patients provided written informed consent before entering the study, which was conducted in compliance with the 1989 Declaration of Helsinki.
ELECTROPHYSIOLOGY STUDY A 12 lead ECG was recorded at the following times: at rest at the prestudy examination; during the baseline period; at 7.5, 15, 20, 30, 40, 50, 60, 65, and 75 minutes after the start of drug infusion; and at 1, 2, 4, 8, 10, and 24 hours after completion of the maintenance infusion.
For arrhythmia induction and intracardiac recording, multipolar electrode catheters were inserted transvenously and positioned under fluoroscopy in the high lateral right atrium, in the right ventricle, and across the tricuspid valve in the region of the bundle of His; as needed, a multipolar catheter was placed in the coronary sinus. Standard surface ECG leads were displayed and recorded at the same time as the intracardiac recordings on a multichannel electrophysiological recorder at paper speeds of 100-250 mm/s. Body surface and intracardiac recordings were filtered at the appropriate frequencies. Atrial and ventricular pacing was applied at twice the diastolic threshold, using 2 ms rectangular pulses.
During the baseline period (lasting around 60 minutes), standard programmed electrical stimulation protocols were used to measure refractory periods and to attempt induction of atrioventricular re-entrant tachycardia.
The eVective refractory period of the atrium was determined using the extrastimulus method, in which an eight beat train of paced atrial beats (A 1 ), at basic cycle lengths of 400 and 600 ms, was followed by a single premature stimulus (A 2 ). The atrial eVective refractory period was defined as the longest A 1 -A 2 interval that failed to result in an atrial depolarisation. The eVective refractory period of the right ventricle was also determined, using the same extrastimulus technique as for the atrium. The ventricular eVective refractory period was defined as the longest V 1 -V 2 interval that failed to result in premature ventricular depolarisation.
The antegrade and retrograde eVective refractory periods of the accessory pathway were also determined using the extrastimulus method. The antegrade eVective refractory period was defined as the longest premature A 1 -A 2 interval that did not result in ventricular pre-excitation, as manifested by loss of the delta wave in the surface QRS.
The retrograde eVective refractory period was defined as the longest premature V 1 -V 2 interval that did not result in atrial preexcitation, as manifested by normalisation of the retrograde atrial activation sequence.
Single and double atrial extrastimuli at cycle lengths of 600 and 400 ms were given in an attempt to induce orthodromic reciprocating tachycardia. When ventricular to atrial conduction was present, single ventricular extrastimuli at cycle lengths of 600 and 400 ms were also applied.
The tachyarrhythmia was defined as noninducible if < 4 non-stimulated ventricular beats were produced by the above protocol, inducible if > 5 non-stimulated ventricular beats at a frequency > 120 beats/min were produced, and sustained if an inducible arrhythmia lasting > 30 seconds was produced. Once the loading infusions and maintenance dose were completed, programmed electrical stimulation was repeated in an attempt to reinduce atrioventricular re-entrant tachycardia at the end of the maintenance infusion.
Following the electrophysiology study, patients were monitored over the next 24 hours with a Holter recorder.
PLASMA CONCENTRATIONS OF DOFETILIDE
Blood samples were obtained at 7.5, 15, 20, 30, 40, 50, 60, 65, and 75 minutes after the start of drug infusion. Blood plasma samples were stored at −20°C and later analysed using radioimmunoassay techniques. 17 The maximum plasma concentration, C max , and the area under the nine hour dofetilide plasma concentration v time curve, AUC 0-9 , were calculated for each subject.
MEASUREMENTS PR interval and QRS durations were determined from the ECG recordings. The QT interval was measured from the same lead (V 2 if possible) by standard methods, and Bazett's formula was used to calculate QTc (QTc = QT/[60/HR]^, where QT is measured in milliseconds and heart rate is measured in beats/min).
The eYcacy of dofetilide was determined by its ability to prevent the reinduction of an atrioventricular re-entrant tachycardia originally induced at baseline. Responders to dofetilide were defined as patients in whom this tachycardia could not be reinduced; nonresponders were defined as those in whom the tachycardia could be reinduced. In nonresponders, the cycle lengths of the tachycardia were compared before and after intravenous 
ANALYSIS
Response rates were compared using the Cochran-Mantel-Haenszel test to determine the relation between drug dose or plasma concentration and response. Data are reported as mean (SEM). A probability value of p < 0.05 was considered significant.
Results
PATIENTS
Of the 59 patients screened, 51 (41 men, 10 women) were enrolled to the study and 48 were followed to completion. All groups were well balanced with respect to age (mean 39 years; range 18-69 years) and weight (mean 76 kg; range 55-110 kg). Included in the safety but not the eYcacy analysis were three patients who received doses not defined in the original protocol. There were no significant diVerences in PR interval, QRS duration, heart rate, or systemic blood pressure. Incomplete data prevented assessment of the prevalence and type of structural heart disease at baseline.
EFFICACY
Sustained atrioventricular re-entrant tachycardia was induced in all 51 patients before dofetilide infusion. The tachycardia was reinduced in all patients receiving dofetilide at the two lowest doses; however, it was suppressed in patients receiving dofetilide at the three higher doses. The response for each dofetilide dose group is shown in fig 1. Dofetilide was eVective in preventing atrioventricular re-entrant tachycardia in 36% of the patients (11/31) in the three highest dose groups. The dose-response relation was significant (p = 0.009).
The relation of response to AUC 0-9 , for those patients in whom the latter was determined, is shown in table 2. The eYcacy rate was 25% (5/20) for all patients with AUC 0-9 levels of > 10 ng.h/ml. This eYcacy rate increased to 57% (4/7) when data for only patients with AUC 0-9 levels of > 20 ng.h/ml were analysed.
NON-RESPONDERS
In patients in whom atrioventricular re-entrant tachycardia could be reinduced, the change in tachycardia cycle length was measured at each of the five doses (table 3). The greatest increase in cycle length was seen at the 9 µg/kg dose (mean (SEM): 47 (12) ms). Though sample sizes were small, increases in cycle length appeared to be dose dependent in all but the highest dose group (15 µg/kg).
REFRACTORY PERIODS
Atrial and ventricular eVective refractory periods were measured, whenever possible, at basic cycle lengths of 400 and 600 ms. The baseline values and the changes in the refractory periods (table 4) show that dofetilide increased the eVective refractory period in both atrium and ventricle; however, a dose-response relation was not clearly shown. No clear diVerences were seen between the increase in eVective refractory period for responders versus nonresponders. As a result of the variability in the relatively small sample size, no formal statistical analysis was performed. Values are mean (SEM). Values are mean (SEM).
The antegrade refractory period of the accessory pathway could be measured in 23 patients and the retrograde refractory period in 16. As with the atrial and ventricular refractory periods, the eVective refractory period of the accessory pathway was consistently increased, whether measured antegradely or retrogradely (table 4) . Because of the small number of patients and the diYculty in obtaining refractory period measurements for the accessory pathway in all five dosage groups, a clear doseresponse relation could not be demonstrated. However, when individual patient data were examined, non-inducibility appeared to be linked to notable prolongation of the eVective refractory periods in most responders.
In one patient who developed atrial fibrillation before and during the dofetilide infusion (1.5 µg/kg), the minimum RR interval increased from 230 to 235 ms during the dofetilide infusion.
SIDE EFFECTS
Four patients reported side eVects that were considered possibly related to dofetilide treatment. One patient experienced episodes of junctional rhythm and bundle branch block; one patient developed spontaneous atrioventricular re-entrant tachycardia identical to that previously induced in the electrophysiology laboratory; and one patient developed a short lasting episode of hypotension and hypoxia. The only serious side eVect was reported in one patient who developed extrasystoles which degenerated into a new sustained, incessant, supraventricular tachycardia. Treatment was discontinued, and a paced ventricular beat terminated the tachyarrhythmia. No clinically relevant aberrations in haemodynamic or laboratory data were detected in the remaining patients. Four other patients developed transient QTc prolongations of > 600 ms; two of these patients had received 15 µg/kg of dofetilide and the other two had received 1.5 and 6 µg/kg of dofetilide, respectively. Clinical resolution was seen for all treatment related side eVects without subsequent adverse consequences.
Discussion
The main finding of this study is that intravenous dofetilide is a safe and eVective agent for preventing the induction of atrioventricular re-entrant tachycardia. A clear and significant relation between dofetilide dose and antiarrhythmic response was demonstrated, as measured by the inability to reinduce the tachycardia. A minimum dose of 6 µg/kg was necessary for antiarrhythmic eYcacy. A relation between plasma concentrations of dofetilide and eYcacy was also demonstrated, as shown by a 25% eYcacy rate when dofetilide AUC 0-9 was > 10 ng.h/ml and a 57% eYcacy rate when it was > 20 ng.h/ml. These findings are consistent with the recommendations of Lévy, who-using a Sicilian Gambit 18 approach-suggested targeting the potassium current with a class III agent in orthodromic atrioventricular re-entrant tachycardia. 19 Intravenous dofetilide was safe in this patient population. Although four patients developed pronounced QT prolongation, none developed torsade de pointes. As periods of sinus rhythm alternated with paced periods during the electrophysiology study, and as the QT prolongation persisted beyond the completion of the electrophysiology study, it is unlikely that the absence of torsade de pointes was related to the ability to pace during the study.
This investigation is the first to measure dofetilide induced prolongation of both antegrade and retrograde refractoriness in accessory pathways in patients with atrioventricular re-entrant tachycardia. The mechanism of this type of tachycardia is believed to be circus movement re-entry involving the atrioventricular node and an accessory pathway. Whether the tachycardia is orthodromic or antidromic, a critical region in the re-entrant pathway of prolonged refractoriness defines the excitable gap of the circuit and is the target of antiarrhythmic drug action. A drug that increases refractoriness to a suYcient degree in this critical portion of the re-entrant circuit may terminate re-entry by eVectively reducing the excitable gap to zero. 20 Because we examined the eYcacy of dofetilide at five separate doses, there were insuYcient refractory period determinations to perform statistical analyses or draw strong conclusions about the site of action. However, based on the limited refractory results presented here and the very specific class III antiarrhythmic action of dofetilide, it seems probable that when the dose of dofetilide is suYciently large the drug prolongs the refractoriness of a critical site. Given the lack of troublesome side eVects of dofetilide, even at the highest dose, it may be a useful treatment for preventing atrioventricular re-entrant tachycardia.
Dofetilide can be used eVectively to treat other re-entrant supraventricular arrhythmias, atrial fibrillation, and atrial flutter, 14-16 21 22 and it compares favourably with class IC antiarrhythmic agents. 23 The majority of these arrhythmias are caused by circus movement re-entry, in which dofetilide can similarly increase the probability of conduction block at the critical site within re-entrant pathways. Thus the ability of dofetilide to prevent or terminate supraventricular re-entrant arrhythmias is linked to its ability to prolong refractoriness, as reflected in the surface ECG QT interval.
COMPARISON WITH OTHER ANTIARRHYTHMIC
DRUGS
The eYcacy of dofetilide in preventing the induction of atrioventricular re-entrant tachycardia is similar to that of other drugs used to treat this arrhythmia: 31% for flecainide, 24 31-50% for propafenone, [24] [25] [26] 30% for amiodarone, 27 and 33% for sotalol. 26 However, these other drugs-along with additional agents suggested for the treatment of atrioventricular re-entrant tachycardia-have significant side eVects. Class I agents are proarrhythmic and have negative inotropic and negative dromotropic eVects. 8 The class III agent sotalol produces hypotension and has significant
